Up to EUR 75M from Kreos Capital and Claret European Growth CapitalUp to EUR 75M from Heights Capital ManagementEUR 27M…
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA…
VANCOUVER, BC / ACCESSWIRE / August 18, 2023 / EMPOWER CLINICS INC (CSE:EPW)(OTC PINK:EPWCF) ("Empower" or the "Company") an integrated…
First stem cell clinical trial landscape is revolutionized by Beauty-Stem Biomedical and Taiwan Tzu Chi Hospital, unveiling the progress of…
MB22001 has been manufactured ready for use in Phase 2 clinical trialsWorld first take-home approvals for psychedelic microdosingVANCOUVER, BC /…
NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing…
Poster presentation at National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 highlights effective prophylaxis, control of bleeding episodes, and consistent…
Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variantUpdated…
Company on track to report top line data in late October 2023SAN FRANCISCO, CA / ACCESSWIRE / August 17, 2023…
Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development…